HIV therapeutic vaccines: moving towards a functional cure. (August 2015)

• Record Type: Journal Article
• Authors: Mylvaganam, Geetha H; Silvestri, Guido; Amara, Rama Rao
• Is Part Of: Current opinion in immunology. Volume 35(2015)
• Page Start: 1
• Page End: 8
• Publication Date: 2015-08
• Subjects: Immunology -- Periodicals; Allergy -- Periodicals; Immunology -- Abstracts -- Periodicals; Allergy -- Abstracts -- Periodicals; 616.079
• DOI: 10.1016/j.coi.2015.05.001
• Languages: English
• ISSNs: 0952-7915

Abstract

Highlights: Therapeutic vaccines can enhance anti-viral T cell immunity. Autologous virus-pulsed DC based vaccines provide a therapeutic benefit. Antibody based immunotherapy shows promise in controlling HIV replication. Combination approaches are needed to achieve a functional cure. Abstract : Anti-viral T-cell and B-cell responses play a crucial role in suppressing HIV and SIV replication during chronic infection. However, these infections are rarely controlled by the host immune response, and most infected individuals need lifelong antiretroviral therapy (ART). Recent advances in our understanding of how anti-HIV immune responses are elicited and regulated prompted a surge of interest in harnessing these responses to reduce the HIV 'residual disease' that is present in ART-treated HIV-infected individuals. Novel approaches that are currently explored include both conventional therapeutic vaccines (i.e., active immunization strategies using HIV-derived immunogens) as well as the use of checkpoint blockers such as anti-PD-1 antibodies. These approaches appear promising as key components of complex therapeutic strategies aimed at curing HIV infection.